Trial · NCT02253173
Registered outcomes48
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 48
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Co-Primary Efficacy Endpoint - Vaginal Superficial Cells | Baseline and 12 Weeks | • Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo |
| Primary | Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells | Baseline and 12 Weeks | • Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo |
| Primary | Co-Primary Efficacy Endpoint - Vaginal pH | Baseline and 12 Weeks | • Change from Baseline to Week 12 in vaginal pH as compared to placebo |
| Primary | Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia) | Baseline and Week 12 | • Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12 |
| Secondary | Secondary Efficacy Endpoints - Vaginal Superficial Cells | Baseline and Week 2 | • Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo |
| Secondary | Secondary Efficacy Endpoints- Vaginal Superficial Cells | Baseline and Week 6 | Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo |
| Secondary | Secondary Efficacy Endpoints - Vaginal Superficial Cells | Baseline and Week 8 | Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo |
| Secondary | Secondary Efficacy Endpoints - Vaginal Parabasal Cells | Baseline and Week 2 | Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo |
| Secondary | Secondary Efficacy Endpoints - Vaginal Parabasal Cells | Baseline and Week 6 | Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo |
| Secondary | Secondary Efficacy Endpoints - Vaginal Parabasal Cells | Baseline and Week 8 | Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo |
| Secondary | Secondary Efficacy Endpoints - Vaginal pH | Baseline and Week 2 | Change from Baseline to Week 2 in vaginal pH as compared to placebo |
| Secondary | Secondary Efficacy Endpoints - Vaginal pH | Baseline and Week 6 | Change from Baseline to Week 6 in vaginal pH as compared to placebo |
| Secondary | Secondary Efficacy Endpoints - Vaginal pH | Baseline and Week 8 | Change from Baseline to Week 8 in vaginal pH as compared to placebo |
| Secondary | Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) | Baseline and Week 2 | Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2 |
| Secondary | Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) | Baseline and Week 6 | Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6 |
| Secondary | Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) | Baseline and Week 8 | Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8 |
| Secondary | Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) | Baseline and Week 2 | Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2 |
| Secondary | Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) | Baseline and Week 6 | Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6 |
| Secondary | Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) | Baseline and Week 8 | Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8 |
| Secondary | Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) | Baseline and Week 12 | Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02253173/registered